Archive for the ‘Pharma’ Category

The Balanced Adherence Metric (BAM): a new spin on current methods for calculating adherence with pharmacy claims data

The Balanced Adherence Metric (BAM): a new spin on current methods for calculating adherence with pharmacy claims data.   Bill Simpson, B.Sc, Ph.D (1,2) and Amos Adler, M.Sc. (2)   McMaster University, Hamilton, Ontario, Canada MEMOTEXT Corporation, Toronto, Ontario, Canada   Purpose/Objective: While Proportion of Days Covered (PDC) quantifies adherence (from claims data) in patients

READ MORE

From the MedX Mainstage to the TSX (Toronto Stock Exchange)

Looking back on MEMOTEXT’s accomplishments this fall

Posted on December 2, 2015 by Noah Nemoy

This autumn has been an exciting time for MEMOTEXT. In September our Founder and President Amos Adler had the opportunity to be a main stage speaker at Stanford Medicine X 2015. Presenting the abstract: “Using Disparate Data to Personalize Digital Health Behavior Change Interventions” Amos rocked the crowd explaining the MEMOTEXT methodology. He had a fantastic time at the event and the “Cat pics + health data = behavior change” line got a substantial amount of press coverage.

READ MORE

If I had $290 billion: Breaking Down the Cost of Medication Compliance

Posted on November 05, 2015 by Noah Nemoy

Medication Compliance is one of the biggest costs to worldwide healthcare systems. 50% of all patients do not take their medication as prescribed and this costs the U.S. healthcare system alone $290 billion per year. That’s a pretty massive figure that can be interpreted in several ways.

We can start by breaking down that $290 billion to show exactly how low compliance rates create such a huge cost:

READ MORE

MEMOTEXT Founder and President Amos Adler to Present at Stanford Medicine X 2015

Abstract: “Using Disparate Data to Personalize Digital Health Behavior Change Interventions” to be presented at conference main stage

Toronto, ON September 16, 2015 – MEMOTEXT is pleased to announce that our Founder and President Amos Adler will be a main stage speaker at Stanford Medicine X 2015. Running from September 23-27 in the heart of Silicon Valley, Medicine X is a catalyst for sharing new ideas on the intersection of healthcare and emerging technologies. Hosted by Stanford University, Medicine X brings together both business and academia for a 4 day conversation on the future of healthcare.

READ MORE

MEMOTEXT Presents at the Pittsburgh Science of Medication Adherence:

Director of Scientific Development Bill Simpson unveils our new BAM adherence metric

Posted on June 26, 2015 by Bill Simpson

2 weeks ago MEMOTEXT had the privilege of presenting our new Balanced Adherence Metric (BAM) at the inaugural Science of Medication Adherence Conference (SMA2015), hosted by the University of Pittsburgh Centre for Pharmaceutical Policy and Prescribing.

READ MORE

MEMOTEXT and PerformRx Co-Present HealthNHand’s PBM and Health Plan Enrolled- Asthma Patient Adherence Case Study

Posted on June 17, 2015 by Noah Nemoy

On Monday morning, MEMOTEXT’s Founder and President Amos Adler and PerformRx’s Director of Drug Therapy Management Programs & Outcomes Lauren C. Megargell, had the honor to jointly present the results of our HealthNHandSM asthma adherence program to the The Digital Transformation of Patient Care: New Avenues for Pharma Growth Seminar. The seminar was organized by the Consulate General of Canada in New York’s Canadian Technology Accelerator (CTA) Health IT Philadelphia as part of BIO2015.

READ MORE

MEMOTEXT Corp. Validating New Adherence Metric: The Balanced Adherence Metric (BAM)

MEMOTEXT to present at both Washington D.C.’s Health Datapalooza 2015 and Pittsburgh’s SMA 2015 this week

Washington, D.C. June 1, 2015 – MEMOTEXT Corp. announces today the upcoming presentation of the Balanced Adherence Metric (BAM). The BAM will be presented tomorrow by MEMOTEXT’s Director of Scientific Development Bill Simpson, Ph.D. Candidate in Neuroscience, at the inaugural Science of Medication Adherence conference (SMA 2015) at the University of Pittsburgh. MEMOTEXT also has a delegation at Washington D.C.’s Health Datapalooza 2015 including Founder and President of MEMOTEXT Amos Adler, M.Sc. Health Datapalooza 2015 runs from today until Wednesday and MEMOTEXT will be present for the entire duration.

READ MORE

PerformRx and MEMOTEXT to present HealthNHand at CTA Health IT Philadelphia:

Attendees can expect to learn about a successful collaborative case study in digital health personalization and adherence engagement

Posted on May 28, 2015 by Noah Nemoy

PerformRx and MEMOTEXT Corp. are pleased to announce their joint presentation on HealthNHandSM at the Consulate General of Canada’s The Digital Transformation of Patient Care: New Avenues for Pharma Growth Seminar in Philadelphia, on June 15th. HealthNHand is being cited as successful case study, in both digital health personalization and adherence engagement.

READ MORE

BAM! A New and Improved Adherence Metric

MEMOTEXT Validates the Balanced Adherence Metric (BAM)

Posted on May 28, 2015 by Noah Nemoy

Finding ways to accurately measure medication adherence can be difficult. Currently, most metrics use pharmacy claims data to measure an individual’s adherence. Many academics and professionals use measures like Proportion of Days Covered (PDC) or Medication Possession Ratio (MPR). But while these measures have several advantages, they don’t account for other adherence factors, such as delay to refill and medication persistence. To solve the problem, MEMOTEXT developed the Balanced Adherence Metric (BAM). BAM amalgamates the four most common adherence measures, providing a more accurate and holistic metric.

READ MORE

MEMOTEXT Does it’s Part to Help Fight Glaucoma

Posted on March 11, 2015 by Noah Nemoy

This March 8-15, is World Glaucoma Week. Launched 6 years ago by the World Glaucoma Association and The World Glaucoma Patient Association, events are being held across the world to raise awareness about Glaucoma. Afflicting 9 million people, Glaucoma is the world’s leading cause of irreversible blindness. Due to its slow progression, 50% of patients in the developed world and 90% in the developing world are untreated. While Glaucoma is currently incurable, with early detection and treatment, its progression can be halted.

READ MORE
Back to Top